AMGNAmgen
$414.93+54% 1Y
$414.93
$265.4052 weeks$444.20
AMGN in its own filings
Nothing in AMGN's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
573
Events found in the filings · across 3,193 filings · the record starts in 1994
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Mar 28, 1994
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Security removed from listing or deregistered3 occurrences · usually a matured note or preferred class, not the common shares
- 2026-02-24
- SEC comment-letter activity42 occurrences
- 2024-05-10
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 31, 2026In July 2026, Amgen Inc. (the "Company") identified unauthorized activity involving data stored in cloud environments hosted by third-party cloud service providers.Material cybersecurity incident · Form 8-K
- May 19, 2026Retirement of Peter H. Griffith, Chief Financial Officer On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.Director or officer change · Form 8-K
- Apr 22, 2026On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer.Director or officer change · Form 8-K
- Feb 19, 2026On February 17, 2026, Amgen Inc. (the “Company”) issued and sold $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031 (the “2031 Notes”), $1,750,000,000 aggregate principal amount of the Company’s 4.850% Senior Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal …Material agreement entered · Form 8-K
- Jan 30, 2026On January 30, 2026, Amgen Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kyowa Kirin Co., Ltd. (“Kyowa Kirin”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “License and Collaboration …Material agreement terminated · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, General
The closest names by size in the same industry